• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Endo Pharmaceuticals

edit

Endo Pharmaceuticals Holdings Inc., through its subsidiary, Endo Pharmaceuticals Inc., engages in the research, development, manufacture, marketing, and sale of branded and generic prescription pharmaceuticals in the United States. Its primary products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana and Opana ER, and Percocet for the relief of moderate to severe pain; Voltaren Gel for use in treating pain associated with osteoarthritis; Frova for the acute treatment of migraine headaches in adults; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas for the palliative treatment of advanced prostate cancer; Valstar, a sterile solution for intravesical instillation of valrubicin and BCG-refractory CIS of the bladder; Hydron Implant, a reservoir-based drug delivery system available for parenteral administration; Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; and Sanctura XR to treat OAB symptoms. The company also offers generic products, including Endocet and morphine sulfate. In addition, it provides various development stage products, which primarily comprise Aveed for the treatment of male hypogonadism; Fortesta for testosterone replacement therapy in male hypogonadism; Octreotide implant for the treatment of acromegaly; Urocidin for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing; and Axomadol in Phase II development for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company has a strategic alliance agreement with Penwest Pharmaceuticals Co. Endo Pharmaceuticals Holdings was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania.

Recent Milestones

edit

• 
  Endo Pharmaceuticals added Rajiv De Silva as President and CEO. (2/25/13)
  Posted 3/1/13 at 4:25pm
• 
  Endo Pharmaceuticals acquired Penwest for $168M. (8/10/10)
  Posted 8/10/10 at 10:47am via fiercebiotech.com
• 
  Endo Pharmaceuticals acquired HealthTronics for $223M. (5/6/10)
  Posted 5/9/10 at 7:57pm via fiercebiotech.com
• 
  Went public with stock symbol NASDAQ:ENDP. (7/18/00)
  Posted 5/9/10 at 7:43pm
• 
  Endo Pharmaceuticals added David P. Holveck as President & CEO.
  Posted 5/9/10 at 7:41pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 5/10/10

Stock Price

Sources

1. Endo buying partner in pain Penwest for $168M Read more: Endo buying partner in pain Penwest for $168M - FierceBiotech http://www.fiercebiotech.com/story/endo-buying-partner-pain-penwest-168m/2010-08-10?utm_medium=rss&utm_source=rss#ixzz0wELAOIx4 Subscri (fiercebiotech.com) [edit]
2. Endo Pharma to buy HealthTronics in $223M deal (fiercebiotech.com) [edit]